Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-09-09

Clinical Trial Update: Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 imaging trial of the radiopharmaceutical I-124-CLR1404 for glioblastoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • I-124-CLR1404

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED